Trastuzumab Deruxtecan: Targeted Therapy for Breast Cancer
Keywords:
Trastuzumab Deruxtecan, targeted therapy, breast cancer, HR-positive, HER2- positiveAbstract
Breast cancer is one of the most common cancers and the leading cause of death in women worldwide. Breast cancer is caused by atypical mitoses in breast. Epithelial tissue that develop from duct cells and lobule cells is also the most common site for the development of cancers. According to etiology, breast cancers have been classified into four subtypes including of HR-positive, HER2- positive, both HR and HER2 Positive and Triple-negative.
Trastuzumab Deruxtecan is a monoclonal antibody-drug conjugate that is topoisomerase I inhibitor. It was more effective than chemotherapy in terms of survival and progression-free survival. However, there is a greater chance of adverse reactions than with chemotherapy. It is also toxic to the embryo and fetus. It is a contraindication for pregnancy.
References
WCRF International. Worldwide cancer data. 2021. [cited October 13, 2024] Available from https://www.wcrf.org/cancer-trends/worldwide-cancer-data/#:~:text=Find%20information%20about%20world%20cancer,and%208.8%20million%20in%20women.
WCRF International. Breast cancer statistics. 2021. [cited October 13, 2024]. Available from https://www.rxlist.com/trastuzumab_deruxtecan/generic-drug.htm
The Global Cancer Observatory. Thailand. 2021. [cited October 13, 2024]. Available from https://gco.iarc.fr/today/data/factsheets/populations/764-thailand-fact-sheets.pdf
Ministry of Public Health. Report on health behavior assessment: self-examination of women aged 35 years and over. Nonthaburi: Printing Agriculture Cooperatives of Thailand; 2005.
Choi L. Breast Cancer. 2022. [cited October 13, 2024]. Available from https://www.msdmanuals.com/professional/gynecology-and-obstetrics/breast-disorders/breast-cancer
Panvichian R. Genomics, Targeted therapy of Breast cancer. Bangkok : Department of Internal Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University; 2022.
Thai Health Stat. Breast cancer. 2022. [cited October 13, 2024]. Available from https://www.hiso.or.th/thaihealthstat/area/index.php?ma=1&pf=01818101&tm=2&tp=13_4&type=1
Medical Record and Databased Cancer Unit. Breast. Cancer in Thailand, 2016-2018. 2021;10(1):43.
Ministry of Public Health. National Cancer Control Programme. 2019. [cited October 13, 2024]. Available from: http://www.nci.go.th/th/File_download/D_index/
Piya-isarakul S. Molecular classification of breast cancer. Asian Archives of Pathology 2020;2(1):14-5.
Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, et al. US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status. JNCI 2014;106(5):1-8. doi:10.1093/jnci/dju055.
Rakchob T. A Cohort Study of Impact of Surgery Types on Recurrence and Metastasis of Breast Cancer in the Young. Med J Srisaket Surin Buriram Hospitals 2021;36(1):169-79.
Tewthanom K, Cherachat C, Sukkasem C, Somwangprasert C, Pornbunjerd S. Breast cancer therapy and cardiotoxicity of Trastuzumab in Breast cancer patients. Veridian E-Journal 2017;4(2):1-18.
Indini A, Rijavec E, Grossi F. Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors. Int J Mol Sci 2021;22(9):4774. doi:10.3390/ijms22094774.
Gustavo A. Trastuzumab Deruxtecan. 2022. [cited October 13, 2024]. Available from https://www.sciencedirect.com/topics/medicine-and-dentistry/trastuzumab-deruxtecan
Azar I, Alkassis S, Fukui J, Alsawah F, Fedak K, Sukari A, et al. Spotlight on Trastuzumab Deruxtecan (DS-8201, T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer. 2021. [cited October 13, 2024]. Available from https://www.dovepress.com/spotlight-on-trastuzumab-deruxtecan-ds-8201t-dxd-for-her2-mutation-pos-peer-reviewed-fulltext-article-LCTT
Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med 2022; 387(1): 9-20. doi:10.1056/NEJMoa2203690.
Jacob D. TRASTUZUMAB DERUXTECAN. 2022. [cited October 13, 2024]. Available from https://www.rxlist.com/trastuzumab_deruxtecan/generic-drug.htm
Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med 2020;382(7):610-21. doi:10.1056/NEJMoa1914510.
André F, Hee Park Y, Kim SB, Takano T, Im SA, Borges G, et al. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet 2023;401(10390):1773-85. doi:10.1016/S0140-6736(23)00725-0.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Srinagarind Medical Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
